Aspirin Resistance Following Coronary Bypass Surgery
Not Applicable
Terminated
- Conditions
- Ischemic Heart Disease
- Registration Number
- NCT00260377
- Lead Sponsor
- Sheba Medical Center
- Brief Summary
Aspirin was proved to be the drug preventing vein grafts from closure and improving clinical outcome after coronary artery bypass surgery. It appears to be effective when being prescribed as early as first 48 hr. after the operation without increasing the incidence of bleeding complications. the exact effective dose is not known.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients undergoing Coronary artery bypass surgery
- Patients who signed Informed Consent Form
Exclusion Criteria
- Concomitant valve surgery or carotid surgery or off-pump surgery
- Need for anticoagulation therapy for any reason
- Another antiplatelet medications at least 7 days prior to surgery
- Contra-indication for aspirin treatment
- Thrombocytopenia / thrombocytopathia
- NSAIDs treatment for chronic medical conditions
- Reluctance to participate in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Ventilation Inotropic support Mortality Perioperative MI Perioperative stroke Bleeding / reopen / transfusion Dysrhythmias
- Secondary Outcome Measures
Name Time Method ICU stay In-hospital stay Non-fatal cardiac events - MI, recurrence of angina, dysrhythmias Need for repeat revascularization
Trial Locations
- Locations (1)
Sheba Medical Center
🇮🇱Ramat-Gan, Israel